Compare EVC & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | OABI |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 239.0M |
| IPO Year | 2000 | N/A |
| Metric | EVC | OABI |
|---|---|---|
| Price | $2.73 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 335.2K | ★ 518.6K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,178,000.00 | $21,094,000.00 |
| Revenue This Year | $64.06 | N/A |
| Revenue Next Year | N/A | $66.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.96 | 3.36 |
| 52 Week Low | $1.58 | $1.22 |
| 52 Week High | $3.15 | $4.17 |
| Indicator | EVC | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 65.31 |
| Support Level | $2.75 | $1.69 |
| Resistance Level | $2.85 | $1.64 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 60.94 | 86.06 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.